

Indication	Summary	Eligibility Criteria	Sponsor	Physician	Contact
Cancer: Solid Tumors & Hematologic Malignancies	Patients with cancer, who've had at least one previous treatment and whose tumor tissue shows a specific genetic mutation, could be eligible for one of five clinical trials each testing a novel oral agent.		Novartis	Dr. Schmidt	Christine Reed 541-706-6592 creed@ bmctotalcare.com
Asthma	Clinical trial comparing the risk of asthma-related events of two FDA approved drugs	Asthma, an asthma exacerbation in the past year, currently taking asthma medication, age 12 or greater	AstraZeneca	Dr. Williams	Mollie Ball 541-706-6594 mball@ bmctotalcare.com
Asthma	Study to evaluate predictors of clinical effectiveness in response to omalizumab (Xolair)	Asthma, identified as a candidate for treatment with omalizumab (Xolair), age 12 or greater	Hoffman-LaRoche	Dr. Williams	Mollie Ball 541-706-6594 mball@ bmctotalcare.com
Asthma, Adolescent	Assess the efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma who are on inhaled corticosteroids and a second controller medication	Asthma, taking eligible asthma medications for 6 months or more, asthma not currently well-controlled, age 12-17	Hoffman-LaRoche	Dr. Williams	Lisa Baert 541-706-6590 lbaert@ bmctotalcare.com
Asthma, Pediatric	Testing a novel medicinal delivery system (Jettpak) in children with asthma	Asthma, child (age 18 months to 10 years) who is taking inhaled corticosteroids for asthma	JettStream	Dr. Williams	Mollie Ball 541-706-6594 mball@ bmctotalcare.com
Breast Cancer, Starting Chemotherapy	Comparing Naproxen (Aleve) or Loratadine (Claritin) to relieve bone pain in breast cancer patients receiving Chemo and Pegfilgrastim	Females with newly diagnosed, not previously treated with chemotherapy, stage I-III breast cancer	Amgen	Dr. West	Mollie Ball 541-706-6594 mball@ bmctotalcare.com
Breast Cancer, Starting Chemotherapy	Comparing educational DVDs to see if education can relieve bone pain in breast cancer patients receiving Chemo and Pegfilgrastim	Females with newly diagnosed, not previously treated with chemotherapy, stage I-III breast cancer	Amgen	Dr. West	Mollie Ball 541-706-6594 mball@ bmctotalcare.com

<i>C. difficile</i> vaccine	Efficacy, immunogenicity, and safety study of <i>Clostridium difficile</i> vaccine in subjects at risk of <i>C. difficile</i> infection	At least 2 hospital stays AND received systemic antibiotics in past year OR anticipated hospitalization for surgery, age $\geq$ 50	Sanofi Pasteur	Dr. Lutz	Anne Bergin 541-706-6597 abergin@ bmctotalcare.com
Diabetes, Type 1 Screening	Testing for auto-antibodies in patients with a first degree relative who has type 1 diabetes	Have a blood relative with type 1 diabetes, patient entering study must not have diabetes, age 1-45	NIH/TrialNet	Dr. Carroll	Jennifer McCormick 541-706-6595 jmccormick@ bmctotalcare.com
Diabetes, Type 2	Evaluate whether a novel device, that releases Byetta (exenatide) under the skin, improves cardiovascular outcomes in patients with type 2 diabetes	Type 2 diabetes, increased cardiovascular risk, age 40 or greater	Intarcia Therapeutics	Dr. Carroll	Anne Bergin 541-706-6597 abergin@ bmctotalcare.com
Gout with Cardiovascular Disease	Clinical trial comparing two FDA approved drugs for the prevention of gout flares	Gout with uric acid $\geq$ 7 or flare in the last 12 months, history of cardiovascular disease	Takeda	Dr. Borstad	Christine Reed 541-706-6592 creed@ bmctotalcare.com
Hyperlipidemia	Evaluate the impact of adding investigational drug to standard statin therapy on reduction of cardiovascular events	History of myocardial infarction (MI) or stroke, and type 2 diabetes or another risk factor, age 40-80	Amgen	Dr. Harris	Jennifer McCormick 541-706-6595 jmccormick@ bmctotalcare.com
Non-Hodgkin Lymphoma	Study of Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib) in combination with other medications in patients with previously treated indolent non-hodgkin lymphoma	Indolent non-hodgkin lymphoma, at least one prior treatment with a CD20 antibody combination chemotherapy regimen, disease that has relapsed or was refractory after prior chemoimmunotherapy	Janssen	Dr. Schmidt	Lisa Baert 541-706-6590 lbaert@ bmctotalcare.com